Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butane SCHEMBL439259 | 0.78 | GABRA1 (0.35) | GABRA1GABRB2 | |
| Methoxymethane SCHEMBL6106068 | 0.74 | GSR (0.32) | POLBTDP1LMNA | |
| Methyl Alcohol SCHEMBL28845780 | 0.73 | GSR (0.35) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| Ether SCHEMBL16296434 | 0.71 | ESR1 (0.41) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2212596 | 0.69 | GSR (0.36) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| SCHEMBL916303 | 0.69 | GSR (0.36) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| Ether SCHEMBL7435965 | 0.69 | ALDH1A1 (0.50) | ALDH1A1TSHRLMNA | |
| SCHEMBL8399642 | 0.69 | GSR (0.36) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| Water SCHEMBL8171778 | 0.69 | — | — | |
| Ether SCHEMBL135123 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008962-B2 | IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050267165-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
| EP-1284956-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1261328-B1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1261328-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | disclosed |
| EP-1284956-A1 | IL-8 RECEPTOR ANTAGONISTS | Smithkline Beecham (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20030032802-A1 | IL8-receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | disclosed |
| EP-1261328-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001092202-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001064208-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032802-A1 | IL8-receptor antagonists | CXCL8, CCR8, IL18 | ALDH1A1 1129/4885MEN1 2975/4885POLB 4058/4885 |
| US-20050267165-A1 | IL-8 RECEPTOR ANTAGONISTS | CXCL8, CCR8, IL18 | ALDH1A1 915/4885MEN1 3643/4885POLB 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.